Novartis Options Quark's Phase II p53 Inhibitor

The agreement comes as Quark weighs going public on the Tel-Aviv Stock Exchange, a move a company official said would position the firm to meet its ultimate goal of floating its shares on the Nasdaq.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.